Table 1. TGFB1 and Rho kinase inhibitors.

Transforming growth factor-b1 (TGFB1) inhibitors

Company

Product

Disease category

Indication

Development

InterMune Inc. (NASDAQ:ITMN)

Esbriet pirfenidone

Pulmonary disease

Pulmonary fibrosis

Marketed in Europe and Canada

Acceleron Pharma Inc./Celgene Corp. (NASDAQ:CELG)

ACE-536

Hematology

Anemia and thalassemia

Phase II

Digna Biotech S.L.

Disitertide (P144)

Autoimmune disease

Scleroderma

Phase II

Digna Biotech

Disitertide (P144)

Dermatology

Dermatology

Phase II

Eli Lilly and Co. (NYSE:LLY)

LY2382770

Renal disease

Diabetic nephropathy and renal disease

Phase II

Renovo Group plc (LSE:RNVO)

Juvidex

Dermatology

Scars and wrinkles

Phase II

Yuhan Corp.

YH14618

Musculoskeletal disease

Cartilage repair

Phase I/II

Digna Biotech

Disitertide (P144)

Dermatology

Actinic keratosis

Phase I

Rho kinase inhibitors

Asahi Kasei Pharma Corp.

Eril fasudil

Cardiovascular disease

Aneurysm

Marketed

D. Western Therapeutics Institute Inc. (JASDAQ:4576)

K-115

Ophthalmic disease

Glaucoma and ocular hypertension

Phase III

Aerie Pharmaceuticals Inc.

AR-13324

Ophthalmic disease

Glaucoma

Phase II

Amakem N.V.

AMA0076

Ophthalmic disease

Glaucoma and ocular hypertension

Phase II

Asahi Kasei Pharma

ATS907

Ophthalmic disease

Glaucoma

Phase II

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508)

Y-39983

Ophthalmic disease

Glaucoma

Phase II

Aerie Pharmaceuticals

AR-12286

Ophthalmic disease

Glaucoma

Phase II/III